Max Bayer / endpoints - CMS plans to launch a new drug payment model for state Medicaid programs, the first of potentially multiple pricing models under President Donald Trump's "most favored nation" push that the pharma industry has been closely ...
AI Summary: The Centers for Medicare and Medicaid Services has introduced a novel Medicaid drug payment model that employs a most-favored nation pricing strategy, aiming to rein in healthcare spending. This bold move signals a shift toward competitive pricing that, while promising cost efficiencies, also raises eyebrows over its unorthodox approach.
AbbVie sues over Botox selection in Medicare price negotiations / 3 months
HHS drops 340B pilot following court rulings / 3 months
HHS scraps 340B rebate pilot following court rulls / 3 months
FTC settles insulin lawsuit forces Express Scripts policy changes / 3 months
Judge blocks 340B drug pricing pilot program implementation / 4 months
Optum Rx/Caremark and FTC edge toward settlement in insulin case / 2 months
Life-extending prostate cancer drug to be offered to thousands in England / 4 months
StackHealth RSS

StackHealth Time Machine
NorthFeed Inc. Terms and Conditions / Privacy Policy
Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.